RxDoctor Payments Data

Bresta Miranda Palma, MD

Endocrinology, Diabetes & Metabolism · Miami, FLNPI 1467417204

Payments from drug & device makers

$35,524in general payments, 2019–2025

Across 20 payments — averaging $1776.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$31K
  • Boehringer Ingelheim$3K
  • Sanofi-aventis U.S. LLC$1K
  • Aytu Biopharma, Inc.$186
  • Valeritas, Inc.$29
  • Insulet Corporation$26
  • plus $55 from 4 others

What the payments were for

  • Food & beverage$39197%
  • Education$123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,524 in reported general payments places this provider in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$57,459
Medicare patients
296
Services billed
640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide374$482,508
JardianceEmpagliflozin238$214,643
MounjaroTirzepatide105$144,574
TrulicityDulaglutide115$143,150
Tresiba Flextouch U-100Insulin Degludec109$80,465
FarxigaDapagliflozin Propanediol67$52,724
TradjentaLinagliptin56$35,837
JanuviaSitagliptin Phosphate48$33,761
JanumetSitagliptin Phos/Metformin Hcl28$29,297
Humalog Kwikpen U-100Insulin Lispro80$28,126
SynjardyEmpagliflozin/Metformin Hcl23$27,760
Tresiba Flextouch U-200Insulin Degludec21$24,967
RybelsusSemaglutide15$22,297
Fiasp FlextouchInsulin Aspart (Niacinamide)23$17,477
VascepaIcosapent Ethyl32$17,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$12$292,788238 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy$2,932$278,239317 claims
MerckJanuvia, Janumet$16$63,05876 claims
AstraZenecaFarxiga$15$52,72467 claims
AbbVieSynthroid$31,189$7,46677 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →